Revvity (NYSE:RVTY) Sets New 52-Week High - Here's Why

Key Points

• Revvity shares reached a new 52-week high of $152.26, driven mainly by the launch of a child type 1 diabetes screening test, which strengthens the company’s reproductive-health and diagnostics portfolio.
• The company reported quarterly EPS of $1.41 versus $1.21 expected and revenue of $729.69 million, while maintaining fiscal 2026 EPS guidance of $5.30–$5.40.
• Despite strong momentum, analysts remain cautious: Revvity has a consensus “Hold” rating and an average price target of $116.57, while its elevated valuation and recent insider stock sales present potential headwinds.

Revvity Inc. (NYSE:RVTY - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday. The stock traded as high as $152.26 and last traded at $150.9550, with a volume of 2539808 shares. The stock had previously closed at $142.11.

Key Headlines Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: The new test provides a commercial and strategic catalyst for Revvity (RVTY), strengthening its position in reproductive health and disease-risk diagnostics. The announcement was cited as the main reason shares moved higher and helped keep the stock near its 52-week high. Revvity Shares Rise on Launch of Child Type 1 Diabetes Screening Test
• Positive Sentiment: The recent operating backdrop is supportive: Revvity’s latest quarterly EPS of $1.41 exceeded the $1.21 consensus estimate, while revenue also topped expectations. The company maintained fiscal 2026 EPS guidance of $5.30–$5.40. Why Revvity Is Getting Attention Today
• Neutral Sentiment: Goldman Sachs continues to rate Revvity “Hold,” reflecting a cautious view despite the product news. The stock’s elevated valuation and strong run above its 50-day and 200-day moving averages may limit additional upside unless earnings growth accelerates. Goldman Sachs Remains a Hold on Revvity
• Negative Sentiment: Insider Maxwell Krakowiak sold 1,631 shares for approximately $235,728, reducing his direct ownership by 9.94%. The sale is relatively small and may be routine, but it is a modest sentiment headwind following the stock’s recent advance. Revvity Insider Sells 1,631 Shares

Analyst Ratings Changes

Several research firms have recently commented on RVTY. TD Cowen restated a "buy" rating on shares of Revvity in a report on Wednesday, July 15th. Wolfe Research began coverage on shares of Revvity in a research note on Tuesday, June 2nd. They set a "peer perform" rating on the stock. Wall Street Zen lowered shares of Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 16th. Weiss Ratings raised shares of Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 30th. Finally, Zacks Research upgraded Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Four investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, Revvity has a consensus rating of "Hold" and an average price target of $116.57.

Revvity Stock Performance

The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The stock has a market cap of $16.85 billion, a PE ratio of 71.88, a P/E/G ratio of 2.61 and a beta of 1.09. The business's 50-day moving average price is $123.32 and its 200-day moving average price is $106.18.

Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analysts' expectations of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. Revvity's revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts expect that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity's dividend payout ratio is presently 13.33%.

Insider Buying and Selling at Revvity

In other news, insider Maxwell Krakowiak sold 1,631 shares of the firm's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the sale, the insider owned 14,781 shares of the company's stock, valued at $2,136,297.93. This trade represents a 9.94% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tajinder Vohra sold 7,330 shares of the company's stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the transaction, the insider directly owned 6,635 shares in the company, valued at $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 9,046 shares of company stock valued at $1,277,685. Company insiders own 0.85% of the company's stock.

Hedge Funds Weigh In On Revvity

Hedge funds have recently modified their holdings of the stock. EdgePoint Investment Group Inc. grew its position in Revvity by 3.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company's stock worth $771,044,000 after purchasing an additional 265,204 shares during the last quarter. Jupiter Topco LLC purchased a new position in shares of Revvity in the second quarter worth $961,017,000. Janus Henderson Group PLC raised its holdings in shares of Revvity by 2.3% in the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company's stock worth $731,386,000 after buying an additional 186,956 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Revvity during the second quarter worth $852,070,000. Finally, State Street Corp lifted its stake in shares of Revvity by 0.8% during the second quarter. State Street Corp now owns 4,342,739 shares of the company's stock worth $483,173,000 after buying an additional 32,426 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.